跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
SITAGLIPTIN-METFORMIN - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
SITAGLIPTIN-METFORMIN
Authorized
STANDARD
SITAGLIPTIN-METFORMIN
SIVEM PHARMACEUTICALS ULC
🇨🇦 Health Canada
Approval Date
Apr 6, 2026
Approval ID
10ff474e5cb0e493
Company
SIVEM PHARMACEUTICALS ULC
Type
Standard
Approval Details
Approval Id
10ff474e5cb0e493
Drug Approval Canada Name
SITAGLIPTIN-METFORMIN
Product Name
SITAGLIPTIN-METFORMIN
Status
Marketed
Status Date
2023-02-06
Original Market Date
2023-02-06
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
PRESCRIPTION
Ahfs
68:20.04 , 68:20.05
Atc Original
A10BD07 METFORMIN AND SITAGLIPTIN
Aig Number
0252656003
Company Name
SIVEM PHARMACEUTICALS ULC
Company Address
4705 Dobrin Street Saint-Laurent Quebec Canada H4R 2P7
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Apr 6, 2026
Approval ID
10ff474e5cb0e493
Type
Standard
Back to Health Canada Approvals